Avalyn Pharma is hoping to rake in around $182 million from an IPO, which the biotech will use to take its inhaled versions ...

Pfizer has abandoned work on a PD-L1-targeting drug that was being tested in patients with various cancers. | Pfizer has ...

Kurma Partners has closed its fourth biotech venture capital fund after raising 215 million euros ($252 million) to support ...

While Big Pharmas embarked on a frenzy of acquisitions over recent weeks, Roche’s CEO has explained to Fierce Biotech why the ...

As Sanofi counts down the days before its new leader arrives, the French pharma’s interim CEO acknowledged there had been a ...

Just a few months after ripping up the central nervous system-focused portion of its RIPK1 deal with Rigel Pharmaceuticals, ...

National Cancer Institute Director Anthony Letai, M.D., Ph.D., has attempted to fight back against the “misinformation” ...

AcuityMD has raised $80 million—with a company valuation now nearing $1 billion—to use its artificial intelligence (AI) ...

McKesson let go of a minority share of its medical/surgical solutions division for $1.25 billion to Apollo Funds as part of ...

A little over a year after reabsorbing its anticoagulant abelacimab, Novartis has now terminated two phase 3 trials for the ...

Roche has shared details of fatalities in its phase 3 relapsing multiple sclerosis (RMS) trials, revealing that deaths from ...

Kyverna Therapeutics has unveiled the full results from its registrational trial of miv-cel in stiff person syndrome (SPS), ...